The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Open accessAbstract
BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab. METHODS: We stratified patients with hyperlipidemia according to the risk categories outlined by the Adult Treatment Panel III of the National Cholesterol Education Program. On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Patients with an LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo every 4 weeks. The primary end point was the percent change from baseline in LDL cholesterol, as measured by means of ultracentrifugation, at week 52. RESULTS: Among the 901 patients included in the primary analysis, the overall least-squares mean (±SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0±2.1% (P<0.001). The mean reduction was 55.7±4.2% among patients who underwent background therapy with diet alone, 61.6±2.6% among those who received 10 mg of atorvastatin, 56.8±5.3% among those who received 80 mg of atorvastatin, and 48.5±5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons). Evolocumab treatment also significantly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), and triglycerides. The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back pain. CONCLUSIONS: At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES ClinicalTrials.gov number, NCT01516879.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment of hyperlipidemic patients with monoclonal antibodies that target and inactivate PCSK9 results in increased hepatic LDLR expression and significantly reduced plasma LDL-C40,41.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with PCSK9 inhibitors reduces LDL-C by approximately − 60% [75–79].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [79]
The cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“ASO silencing of Rnf130 resulted in a 50% decrease in LDL-C, a change comparable to inhibiting PCSK940,41, further supporting that RNF130 is a significant regulator of LDLR and LDL-C levels.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 579
Self-citationMcKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Self-citationRaal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 506
Self-citationAtorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 462
Self-citationLambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Self-citationGiugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R. M., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Self-citation
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 722
Chorba, J. S., & Shokat, K. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.594861 · Cited by 37
Latest developments in the treatment of lipoprotein (a)
Bos, S., Yayha, R., & van Lennep, J. E. R. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000126 · Cited by 37
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
Verbeek, R., Stoekenbroek, R. M., & Hovingh, G. K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.099 · Cited by 39
PCSK9 Inhibitors and Cardiovascular Events
Sabatine, M. S., Wasserman, S. M., & Stein, E. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508222 · Cited by 37
Self-citationEfficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6666-1 · Cited by 36
Navarese, E. P., Kołodziejczak, M. M., Dimitroulis, D., Wolff, G., Busch, H. L., Devito, F., Sionís, A., & Ciccone, M. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv045 · Cited by 36
Coronary Heart Disease and Genetic Variants with Low Phospholipase A2 Activity
Polfus, L. M., Gibbs, R. A., & Boerwinkle, E. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1409673 · Cited by 36
Effect of Evolocumab on Lipoprotein Particles
Toth, P. P., Sattar, N. A., Blom, D. J., Martin, S. S., Jones, S. R., Monsalvo, M. L., Elliott, M., Davis, M., Somaratne, R. M., & Preiss, D. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.10.028 · Cited by 36
Self-citationToth, P. P., Jones, S. R., Monsalvo, M. L., Elliott‐Davey, M., López, J. A. G., & Banach, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014129 · Cited by 36
Self-citationRecent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 36
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
Depo-Provera, P. (2015) · Cited by 35
Du, H., Li, X., Su, N., Li, L., Hao, X., Gao, H., Kwong, J. S.-W., Vandvik, P. O., Yang, X., Németh, I., et al. (2019) · Heart · doi:10.1136/heartjnl-2019-314763 · Cited by 36
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 34
Self-citationPharmacological Options in Atherosclerosis: A Review of the Existing Evidence
Gupta, K. K., Ali, S., & Sanghera, R. S. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0123-0 · Cited by 35
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
PCSK9 and infection: A potentially useful or dangerous association?
Khademi, F., Momtazi‐Borojeni, A. A., Reiner, Ž., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26040 · Cited by 33
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 34
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation
Kühl, M., Binner, C., Jozwiak, J., Fischer, J., Hahn, J., Addas, A., Dinov, B., Garbade, J., Hindricks, G., & Borger, M. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210373 · Cited by 33
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 34
Self-citationLong-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 34
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
He, N.-Y., Li, Q., Wu, C., Ren, Z., Gao, Y., Pan, L.-H., Wang, M., Wen, H.-Y., Jiang, Z., Tang, Z., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.134 · Cited by 33
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia
Sun, Y., Lv, Q., Guo, Y., Wang, Z., Huang, R., Gao, X., Han, Y., Yao, Z., Zheng, M., Luo, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.012 · Cited by 32
Bandyopadhyay, D., Ashish, K., Hajra, A., Qureshi, A., & Ghosh, R. K. (2018) · Journal of Lipids · doi:10.1155/2018/3179201 · Cited by 32
Achimastos, A. D., Alexandrides, T., Alexopoulos, D. K., Athyros, V. G., Bargiota, Α., Bilianou, E., Chrysochoou, C., Drogari, E., Elisaf, M., Ganotakis, E., et al. (2016) · HORMONES · doi:10.1007/bf03401398 · Cited by 32
Efficacy and Safety of Inclisiran in Asian Patients
Huo, Y., Lesogor, A., Lee, C. W., Chiang, C.-E., Mena-Madrazo, J., Poh, K. K., Jeong, M. H., Maheux, P., Zhang, M., Wei, S., et al. (2024) · JACC: Asia · doi:10.1016/j.jacasi.2023.09.006 · Cited by 31
Familial hypercholesterolaemia: PCSK9 inhibitors are coming
Santos, R. D., & Watts, G. F. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61702-5 · Cited by 31
Taskinen, M., Björnson, E., Kahri, J., Söderlund, S., Matikainen, N., Porthan, K., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Fermanelli, V., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315446 · Cited by 31
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou, S., & Ray, K. K. (2017) · Heart · doi:10.1136/heartjnl-2016-310844 · Cited by 30
PCSK9 Antibodies for the Treatment of Hypercholesterolemia
Gouni‐Berthold, I., & Berthold, H. K. (2014) · Nutrients · doi:10.3390/nu6125517 · Cited by 30
Statin-Associated Diabetes Mellitus: Review and Clinical Guide
Backes, J. M., Kostoff, M. D., Gibson, C., & Ruisinger, J. F. (2016) · Southern Medical Journal · doi:10.14423/smj.0000000000000423 · Cited by 30
Desai, N. R., Giugliano, R. P., Wasserman, S. M., Gibbs, J. P., Liu, T., Scott, R. C., & Sabatine, M. S. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5395 · Cited by 30
Self-citationChen, Y., Yuan, Z., Lu, J., Eliaschewitz, F. G., Lorenzatti, A. J., Monsalvo, M. L., Wang, N., Hamer, A. W., & Ge, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13700 · Cited by 30
Self-citationPuri, R., Mehta, V., Duell, P. B., Nair, D. R., Mohan, J. C., Yusuf, J., Dalal, J. J., Mishra, S., Kasliwal, R. R., Agarwal, R., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.006 · Cited by 30
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 31
An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
Choi, H. D., & Kim, J. H. (2023) · Cardiovascular Therapeutics · doi:10.1155/2023/7362551 · Cited by 30
Self-citationKashef, A., & Giugliano, G. R. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.35 · Cited by 30
Lee, J., Egolum, U. O., Parihar, H. S., Cooley, M., & Ling, H. (2021) · Cardiology Research · doi:10.14740/cr1224 · Cited by 29
Manejo do risco cardiovascular: dislipidemia
Izar, M. C. D. O., Fonseca, F. A. H., Faludi, A. Á., de Araújo, D. B., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-19 · Cited by 33
Targeting PCSK9 for Therapeutic Gains
Shapiro, M. D., Fazio, S., & Tavori, H. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0499-4 · Cited by 28
PCSK9 inhibition in patients with hypercholesterolemia
Desai, N. R., & Sabatine, M. S. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.01.009 · Cited by 29
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 28
Self-citationElbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1206080 · Cited by 29
Stroes, E. S. G., Robinson, J. G., Raal, F. J., Dufour, R., Sullivan, D., Kassahun, H., Ma, Y., Wasserman, S. M., & Koren, M. J. (2018) · Clinical Cardiology · doi:10.1002/clc.23049 · Cited by 28
Self-citationTargeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
Badia, L. A. D., Elshourbagy, N. A., & Mousa, S. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.011 · Cited by 29
Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors
Jerome, R. N., Pulley, J. M., Roden, D. M., Shirey-Rice, J. K., Bastarache, L. A., Bernard, G. R., Ekstrom, L. B., Lancaster, W. J., & Denny, J. C. (2017) · Drug Safety · doi:10.1007/s40264-017-0616-0 · Cited by 29
Durairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
Dent, R. E., Joshi, R., Djedjos, C. S., Legg, J. C., Elliott, M., Geller, M. L., Meyer, D., Somaratne, R. M., Recknor, C. P., & Weiss, R. (2016) · SpringerPlus · doi:10.1186/s40064-016-1892-3 · Cited by 27
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U., & Luijendijk, H. J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1787832 · Cited by 27
Fischer, L. T., Hochfellner, D. A., Knoll, L., Pöttler, T., Mader, J. K., & Aberer, F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01283-w · Cited by 27
A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021
Wei, N., Hu, Y., Liu, G., Li, S., Yuan, G., Shou, X., Zhang, X., Shi, J., & Zhai, H. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101151 · Cited by 27
Wang, W., He, Y.-F., Chen, Y.-L., Zhao, F., Song, Y., Zhang, H., Ma, Y., Guan, X., Zhang, W.-Y., Chen, X., et al. (2016) · Journal of International Medical Research · doi:10.1177/0300060516648030 · Cited by 27
Targeting low‐density lipoprotein cholesterol with PCSK9 inhibitors
Scherer, D. J., Nelson, A. J., Psaltis, P. J., & Nicholls, S. J. (2017) · Internal Medicine Journal · doi:10.1111/imj.13451 · Cited by 27
Chen, K., Wu, Q., Hu, K.-W., Yang, C., Wu, X., Cheung, P., & Williams, K. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310358 · Cited by 27
Zulkapli, R., Muid, S. A., Wang, S. M., & Nawawi, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065098 · Cited by 27
Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
Li, X., Li, Z.-F., & Wu, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25985 · Cited by 27
Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction
Mitsuda, T., Uemura, Y., Ishii, H., Takemoto, K., Uchikawa, T., Koyasu, M., Ishikawa, S., Miura, A., Imai, R., Iwamiya, S., et al. (2016) · Heart and Vessels · doi:10.1007/s00380-016-0823-0 · Cited by 26
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom, D. J., Dent, R. E., Castro, R. D. C., & Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s102564 · Cited by 27
Self-citationPeng, W., Qiang, F., Peng, W., Qian, Z., Ke, Z., Yi, L., Zhong, J., & Chong-Rong, Q. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.239 · Cited by 26
Gibbs, J. P., Slatter, J. G., Egbuna, O. I., Geller, M. L., Hamilton, L. J., Dias, C. S., Xu, R., Johnson, J., Wasserman, S. M., & Emery, M. G. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.832 · Cited by 26
Self-citationPage, M. M., & Watts, G. F. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13070 · Cited by 27
Evolocumab: First Global Approval
Markham, A. (2015) · Drugs · doi:10.1007/s40265-015-0460-4 · Cited by 26
Jaworski, K., Jankowski, P., & KOSIOR, D. A. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.65239 · Cited by 27
Loss-of-function PCSK9 mutations are not associated with Alzheimer disease
Paquette, M., Saavedra, Y. G. L., Poirier, J., Théroux, L., Dea, D., Baass, A., & Dufour, R. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718764330 · Cited by 26
Okuyama, H., Hamazaki, T., Hama, R., Ogushi, Y., Kobayashi, T., Ohara, N., & Uchino, H. (2018) · Pharmacology · doi:10.1159/000486374 · Cited by 26
Thonusin, C., Apaijai, N., Jaiwongkam, T., Kerdphoo, S., Arunsak, B., Amput, P., Palee, S., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114741 · Cited by 26
AlTurki, A., Marafi, M., Dawas, A., Dubé, M., Vieira, L., Sherman, M. H., Grégoire, J. C., Thanassoulis, G., Tardif, J., & Huynh, T. T. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.011 · Cited by 26
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
Rivera, F. B., Cha, S. W., Linnaeus Louisse, C., Carado, G. P., Magalong, J. V., Tang, V. A., Enriquez, M. G., Gulati, M., Enkhmaa, B., Pagidipati, N., et al. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2024.101549 · Cited by 25
Wang, L., Muthuramu, I., Somanathan, S., Zhang, H., Bell, P. L., He, Z., Yu, H., Zhu, Y., Tretiakova, A. P., & Wilson, J. M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.017 · Cited by 25
Page, M. M., Stefanutti, C., Sniderman, A. D., & Watts, G. F. (2015) · Clinical Science · doi:10.1042/cs20140755 · Cited by 25
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
Hishikari, K., Hikita, H., Nakamura, S., Nakagama, S., Mizusawa, M., Yamamoto, T., Doi, J., Utsugi, Y., Sudo, Y., Kimura, S., et al. (2017) · Journal of Endovascular Therapy · doi:10.1177/1526602817728068 · Cited by 25
The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis
Qin, J., Liu, L., Su, X. D., Wang, B. B., Fu, B. S., Cui, J., & Liu, X. Y. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.026 · Cited by 26
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 26
Bococizumab for the treatment of hypercholesterolaemia
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1279602 · Cited by 24
Franchini, M., Capuzzo, E., & Liumbruno, G. M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2015.0163-15 · Cited by 24
Carroll, C., Tappenden, P., Rafia, R., Hamilton, J. A., Chambers, D., Clowes, M., Durrington, P. N., Qureshi, N., & Wierzbicki, A. S. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0492-6 · Cited by 24
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a)
Ferdinand, K. C., & Nasser, S. A. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6588-3 · Cited by 24
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 23
Homozygous familial hypercholesterolemia: Summarized case reports
Widhalm, K., Benke, I. M., Fritz, M., Geiger, H., Helk, O., Fritsch, M., Hoermann, G., & Kostner, G. M. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.01.002 · Cited by 23
Sucajtys-Szulc, E., Szołkiewicz, M., Świerczyński, J., & Rutkowski, B. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2590-0 · Cited by 22
Khan, S. U., Riaz, H., Rahman, H., Khan, M. U., Khan, M. S., Alkhouli, M. A., Kaluski, E., Leucker, T. M., & Blaha, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.014 · Cited by 24
A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Chen, B., Shi, X., Cui, Y., Hou, A., & Zhao, P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190809094203 · Cited by 22
Landmesser, U., Lindgren, P., Hagström, E., van Hout, B., Villa, G., Pemberton-Ross, P. J., Arellano, J., Svensson, M. K. E., Sibartie, M., & Fonarow, G. C. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa072 · Cited by 22
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez‐Martínez, P., Mora, S., Bilianou, H. I., Panotopoulos, G., Katsiki, N., Ooi, T. C., López‐Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190503123911 · Cited by 23
Profile of evolocumab and its potential in the treatment of hyperlipidemia
Cicero, A. F. G., Colletti, A., & Borghi, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s67498 · Cited by 21
The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia
Patel, R. S., Scopelliti, E. M., & Olugbile, O. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018771670 · Cited by 21
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East
Sayed, N., Waili, K. A., Alawadi, F., Al-Ghamdi, S. M. G., Almahmeed, W. A., Alnouri, F., Rukhaimi, M. A., Al‐Rasadi, K., Awan, Z. A., Farghaly, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.081 · Cited by 22
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Preiss, D., & Mafham, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4178-y · Cited by 21
Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease
Schlegel, V., Treuner-Kaueroff, T., Seehofer, D., Berg, T., Becker, S., Ceglarek, U., Thiery, J., & Kaiser, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181540 · Cited by 22
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Fitzgerald, G., & Kiernan, T. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497975 · Cited by 21
Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Li, T., Yingyi, Z., & Cong, H. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01827-0 · Cited by 21
Levisetti, M. G., Joh, T., Wan, H. I., Liang, H., Forgues, P., Gumbiner, B., & Garzone, P. (2016) · Clinical and Translational Science · doi:10.1111/cts.12430 · Cited by 21
PCSK9 antibodies: A new class of lipid-lowering drugs
Gouni‐Berthold, I. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.003 · Cited by 22
LDL-Cholesterol: Standards of Treatment 2016: A German Perspective
März, W., Scharnagl, H., Gouni‐Berthold, I., Silbernagel, G., Dressel, A., Grammer, T. B., Landmesser, U., Dieplinger, H., Windler, E., & Laufs, U. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0179-y · Cited by 20
Vuorio, A. F., Watts, G. F., & Kovanen, P. T. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx546 · Cited by 21
Busuioc, R., Covic, A. C., Kanbay, M., Banach, M., Burlacu, A., & Mircescu, G. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz108 · Cited by 20
Metadata
- Authors
- Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsirtsonis, K., Kim, J. B., Scott, R., Wasserman, S. M., & Stein, E. A.
- Affiliations
- University of Cape Town (ZA)
- National Institutes of Health (US)
- Midwest Institute for Clinical Research (US)
- Stellenbosch University (ZA)
- Sterling Research Group (US)
- Jacksonville Center for Clinical Research (US)
- Houston Methodist (US)
- Amgen (United States) (US)
- Amgen (United Kingdom) (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-08
- Volume
- 370
- Issue
- 19
- Pages
- 1809-1819
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155259933
- Semantic Scholar
- 8d480541d9ba40d0cf45fea465f3b42bfc2b2f19
- Cited by
- 720
- References
- 16
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 44 · 2023: 44 · 2022: 26 · 2021: 33 · 2020: 46 · 2019: 49 · 2018: 62 · 2017: 92 · 2016: 110 · 2015: 103 · 2014: 48
- FWCI
- 116.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Open University of Cape Town (University of Cape Town) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibition, hyperlipidemia, LDL cholesterol lowering, monoclonal antibodies, atorvastatin, ezetimibe, apolipoprotein B, lipoprotein(a), triglycerides, non-HDL cholesterol, treatment safety
- MeSH terms
- Atorvastatin, Ezetimibe, Proprotein Convertase 9, Adult, Aged, Antibodies, Monoclonal, Azetidines, Combined Modality Therapy, Double-Blind Method, Female, Heptanoic Acids, Humans, Hyperlipidemias, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Serine Endopeptidases, Least-Squares Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
